FBP2 Antibody (1E11) [FITC]
Novus Biologicals, part of Bio-Techne | Catalog # NBP2-22556F
Conjugate
Catalog #
Forumulation
Catalog #
Key Product Details
Species Reactivity
Human
Applications
ELISA, Western Blot
Label
FITC (Excitation = 495 nm, Emission = 519 nm)
Antibody Source
Monoclonal Mouse IgG1 kappa Clone # 1E11
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
Recombinant human FBP2 (1-339aa) purified from E. coli
Clonality
Monoclonal
Host
Mouse
Isotype
IgG1 kappa
Applications for FBP2 Antibody (1E11) [FITC]
Application
Recommended Usage
ELISA
Optimal dilutions of this antibody should be experimentally determined.
Western Blot
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein G purified
Formulation
PBS
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: FBP2
Alternate Names
D-fructose-1,6-bisphosphate 1-phosphohydrolase 2, EC 3.1.3, EC 3.1.3.11, FBPase 2, fructose-1,6-bisphosphatase 2, fructose-1,6-bisphosphatase isozyme 2, hexosediphosphatase, MGC142192, muscle fructose-bisphosphatase
Gene Symbol
FBP2
Additional FBP2 Products
Product Documents for FBP2 Antibody (1E11) [FITC]
Product Specific Notices for FBP2 Antibody (1E11) [FITC]
This conjugate is made on demand. Actual recovery may vary from the stated volume of this product. The volume will be greater than or equal to the unit size stated on the datasheet.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...